The BloodTechNet program was launched in 2011 to facilitate the development of innovative educational resources that support the Transfusion, Cellular Therapy and Transplantation communities in Canada. The program is led by Canadian Blood Services’ Centre for Innovation with financial support from Grifols. For information about the next BloodTechNet program competition, visit blood.ca research funding programs.
The BloodTechNet program was launched in 2011 to facilitate the development of innovative educational resources that support the Transfusion, Cellular Therapy and Transplantation communities in Canada. The program is led by Canadian Blood Services’ Centre for Innovation with financial support from Grifols. For information about the next BloodTechNet program competition, visit blood.ca research funding programs.
The BloodTechNet program was launched in 2011 to facilitate the development of innovative educational resources that support the Transfusion, Cellular Therapy and Transplantation communities in Canada. The program is led by Canadian Blood Services’ Centre for Innovation with financial support from Grifols. For information about the next BloodTechNet program competition, visit blood.ca research funding programs.
A place to share HLA resources and stuff .. Here you will find a general display of what your page could look like. Browse the site to get a general idea of the look and feel of the site and its layout options. We can link out to reports, leading practices and other sites in the second half of this main page. Don't forget to link to this site in other resources so stakeholders, partners, internal and external audiences know to check it out. Website analytics are a great way to capture and report back on #s. Let's get started!
A very small percentage of red blood cell units are manufactured from blood donors with red cell antibodies. These donors may have antibodies directed against common non-ABO antigens detected during routine screening or may represent a rare blood donor with the corresponding antibody.
Authors: Danielle Meunier, MD; Sophia Peng, MD; and Gwen Clarke, MD, FRCPC
Publication date: September 2019
Primary target audiences: Medical laboratory technologists (MLT) in a hospital laboratory, transfusion medicine physicians
Authors: Danielle Meunier, MD; Sophia Peng, MD; and Gwen Clarke, MD, FRCPC
Publication date: September 2019
Primary target audiences: Medical laboratory technologists (MLT) in a hospital laboratory, transfusion medicine physicians
Authors: Danielle Meunier, MD; Sophia Peng, MD; and Gwen Clarke, MD, FRCPC
Publication date: September 2019
Primary target audiences: Medical laboratory technologists (MLT) in a hospital laboratory, transfusion medicine physicians
Authors: Danielle Meunier, MD; Sophia Peng, MD; and Gwen Clarke, MD, FRCPC
Publication date: September 2019
Primary target audiences: Medical laboratory technologists (MLT) in a hospital laboratory, transfusion medicine physicians
Authors: Danielle Meunier, MD; Sophia Peng, MD; and Gwen Clarke, MD, FRCPC
Publication date: September 2019
Primary target audiences: Medical laboratory technologists (MLT) in a hospital laboratory, transfusion medicine physicians
